Compare

AOD-9604 vs Tesamorelin

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

AOD-9604

44 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 98% · Mixed 2% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite
155
Recovery
155

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
2
Injection site irritation
1

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.1 to ≥ 5 mg (open-ended top bucket)

0.1–0.2 mg
4
0.2–0.4 mg
113
0.4–0.6 mg
37
5+ mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.

Overall, repeat reporters leaned similar or mixed compared to their previous entry.

Median gap between entries: 54 days · Based on 30 repeat reporters

Tesamorelin

114 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 3% · Mixed 97% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Appetite
224
Sleep
1
Recovery
1
Libido
1

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site irritation
113
Water retention
106

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 1–2 mg

Reports span 0 to ≥ 5 mg (open-ended top bucket)

0–0.01 mg
9
0.1–0.2 mg
1
0.2–0.4 mg
5
0.4–0.6 mg
5
0.6–1 mg
4
1–2 mg
126
2–3 mg
74
5+ mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 46 days · Based on 41 repeat reporters